“RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus on siRNA, miRNA, shRNA and DNA” Knowpia

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

Key Inclusions

§ A detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders, and others), type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target genes, type of delivery system used, route of administration and special drug designations (if any).

§ A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishment.

§ An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules. The trials were analyzed on the basis of various relevant parameters, such as registration year, current status, phase of development, type of RNAi molecule, regional distribution of clinical trials and enrolled patient population.

§ .

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

§ Key therapeutic areas

§ Oncological disorders

§ Infectious diseases

§ Genetic disorders

§ Ophthalmic disorders

§ Hepatic disorders

§ Respiratory disorders

§ Type of RNAi molecule

§ siRNA

§ miRNA

§ shRNA

§ sshRNA

§ DNA

§ Route of administration

§ Subcutaneous

§ Intravenous

§ Intradermal

§ Intratumoral

§ Intravitreal

§ Oral

§ Intramuscular

§ Key geographical regions

§ North America

§ Europe

§ Asia Pacific and the Rest of the World

§ Leading Players

The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):

Amotz Shemi (Chief Executive Officer, Silenseed)

To request sample pages, please visit this - https://www.rootsanalysis.com/reports/278/request-sample.html

Key Questions Answered

§ Who are the leading industry players in this market?

§ What are the clinical conditions for which RNAi therapeutics are being developed?

§ Who are the key investors in the RNAi therapeutics market?

§ What kind of commercialization strategies are being adopted by RNAi therapeutics developers?

§ What are the different promotional and reimbursement strategies used for RNAi therapeutics?

§ What are the prevalent R&D trends related to RNAi therapeutics?

§ What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?

§ What kind of partnership models are used by stakeholders in this industry?

§ Who are the key service providers in this field of therapeutics?